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Abstract
Purpose Parathyroid carcinoma (PC) is remarkable for its rare
occurrence and challenging diagnostics. PC accounts for 0.1–
5 % cases of primary hyperparathyroidism (PHPT). The dif-
ferentiation from benign tumours is difficult even by morpho-
logical criteria. To address these issues, we assessed the PC
frequency in two separate European PHPT cohorts and eval-
uated the demographic, clinical, morphological and molecular
background.
Methods A retrospective study was carried out, using contin-
uously maintained database (2005–2014) of PHPT patients
from two tertiary referral university hospitals in Europe. The
demographic, clinical data and frequency of PC among surgi-
cally treated PHPT was detected. Immunohistochemistry
(IHC) was performed to detect parafibromin, representing pro-
tein product of HRPT2 gene and proliferation marker Ki-67.
Results Both PHPTcohorts were characterised by close mean
age values (58.6 and 58.0 years) and female predominance.
The frequency of PC differed significantly between the co-
horts: 2.1 vs. 0.3 %; p=0.004. PC was characterised by invari-
able complete loss of parafibromin contrasting with parathy-
roid adenomas. The proliferation fraction was similar in both
PC cohorts (10.6 and 11.0 %). PC showed significantly higher
proliferation fraction than typical parathyroid adenomas
(1.6 %), atypical adenomas (1.6 %) or adenomas featuring
focal loss of parafibromin (2.2 %).
Conclusions PC frequency can range significantly between
the two European cohorts. The differences can be attributable
to selection bias of patients referred for surgery and are not
caused by discordant definition of malignant parathyroid his-
tology. Diffuse loss of parafibromin and increased prolifera-
tion fraction by Ki-67 are valuable adjuncts in PC diagnostics
due to significant differences with various clinical and mor-
phological subtypes of adenoma.
Keywords Parathyroid carcinoma . Primary
hyperparathyroidism . Immunohistochemistry .
Ki-67 . Parafibromin
Introduction
Primary hyperparathyroidism (PHPT) is among the most
common endocrine diseases. It usually results from a single
parathyroid adenoma (PA). Less frequently, tumours can de-
velop in multiple parathyroid glands [1]. Parathyroid carcino-
ma (PC) is the least common endocrine malignancy
representing only 0.005 % of all cancers [2]. PC accounts
for 0.1–5 % of all PHPT in contrary to benign PA causing
approximately 85 % of PHPT cases [3]. Around half of PC
cases are diagnosed at a mean age of 50 years with no sex or
race predilection [4]. Most of the patients present with clinical
and biochemical manifestations of severe hyperparathyroid-
ism, including severe hypercalcemia, elevated parathyroid
hormone (PTH) level as well as renal and osseous complica-
tions [5]. A palpable neck mass is present in 30–76 % of
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Aetiology of PC is largely unknown but history of neck
irradiation is a known risk factor for all neck cancers. There is
no evidence that PC arises from pre-existing benign parathy-
roid lesions [4]. PC can occur sporadically and in 15 % of
cases in association with familial isolated primary hyperpara-
thyroidism and hyperparathyroidism-jaw tumour syndrome
(HPT-JT). This is not the case for other syndromes like mul-
tiple endocrine neoplasia (MEN1, MEN2A) [3, 6].
Intraoperatively, malignant nature is suspected by the
features of local invasion, as well as enlarged and firm to
hard affected gland with greyish white cut surface. The
mean tumour size reaches approximately 3 cm (range, 1–
7 cm), and the average weight ranges around 3 g. However,
tumours as large as 67 g have been reported [5, 7]. The
diagnosis of PC must be confirmed by the World Health
Organisation (WHO) morphological criteria. Extensive in-
vasion of adjacent tissues and metastatic spread represent
the two absolute diagnostic criteria [8]. The other criteria
include focal coagulation necrosis, irregular dense fibrosis
and capsular, vascular or neural invasion. PC most fre-
quently invades the ipsilateral thyroid (89 %), skeletal mus-
cles (71 %), recurrent laryngeal nerve (26 %), oesophagus
(18 %) as well as trachea in 17 % of PC patients [9]. Since
parathyroids can be located inside the thyroid gland, the
mere presence of parathyroid tissue within the thyroid is
not sufficient for diagnosing parathyroid carcinoma. Re-
gional metastases are present in 15 % of cases. Distal me-
tastases in the lungs and bones are rare [9, 10].
Despite the refined morphological criteria, the diagnosis
of PC remains challenging. Over the last decades, physi-
cians, surgeons and pathologists have experienced difficul-
ties in distinguishing PC from benign disease if the patient
was lacking overt invasion and/or metastasis [11]. Among
advances in the knowledge of the molecular pathogenesis
of PC, the identification of the tumour suppressor gene
HRPT2 and the relevant protein, parafibromin have result-
ed in a valuable diagnostic tool. HRPT2 mutations result in
loss of parafibromin that can be assessed by immunohisto-
chemistry—a widely available and cheap tissue investiga-
tion technique [12]. The proliferation marker Ki-67 has
also been characterised as a useful tool, since PC usually
has greater Ki-67 expression than adenomas [13, 14].
However, both groups overlap; therefore, the current
WHO classification guidelines suggest that patients having
Ki-67 expression in more than 5 % of parathyroid tumour
cells should not be diagnosed with clear-cut cancer but
instead should be followed closer due to an increased risk
of malignant course [14].
To address the urgent epidemiological and diagnostic is-
sues, we assessed the PC frequency in two separate European
PHPT cohorts and evaluated the demographic, clinical, mor-
phological and molecular background.
Materials and methods
Study design
The study was performed as a retrospective investigation,
using continuously supplemented database of parathyroidec-
tomies. The database was surgeon-maintained at two tertiary
referral university hospitals—Pauls Stradins Clinical univer-
sity hospital, Riga (Latvia) and Lukas hospital, Neuss (Ger-
many). Patients who were diagnosed with PHPT and
underwent surgical treatment (2005–2014) were identified
within the databases. The inclusion criteria comprised a veri-
fied morphological diagnosis of a parathyroid tumour in a
surgically removed tissue material. Patients with positive fam-
ily history of PHPT, secondary or tertiary hyperparathyroid-
ism were excluded from further analysis. Thus, 982 patients
were eligible for the study, including 288 patients from Latvia
and 694—from Germany. The data on the final diagnosis, age
at the time of operation, sex, main clinical symptoms, preop-
erative serum calcium (Ca) and PTH levels were retrieved.
The frequency of PC among surgically treated PHPT was
detected and compared between the two European cohorts.
Further, data of patients with proven PC were compared to
patients who underwent surgery for benign PHPT.
Surgical pathology evaluation
A retrospective morphological and immunohistochemical in-
vestigation of consecutive surgically treated parathyroid tu-
mours was carried out. The pathology data have been obtained
via uniform, protocol-based gross and microscopic examina-
tion of the parathyroid surgery materials. Grossly, the largest
diameter of a mass lesion was detected, among other findings.
The tissues were sampled widely for microscopic examination
including multiple sections from the tumour capsule and/or
grossly involved adjacent thyroid or soft tissues. The samples
were routinely fixed in neutral buffered formalin, processed,
embedded in paraplast, cut in 3-μm thickness and stained with
haematoxylin and eosin. The slides were examined under light
microscopy to detect histological tumour type in accordance
with the following criteria.
PC was diagnosed either by any one of definitive criteria,
or on the basis of at least three additional criteria. The defin-
itive criteria of PC comprised unequivocal evidence of inva-
sive growth involving the surrounding tissues as the thyroid
gland, soft tissues or oesophagus; or vascular or perineural
invasion; or the presence of regional or distant metastases.
The additional criteria included capsular invasion, mitotic ac-
tivity exceeding five mitoses/ten high power fields, broad fi-
brotic bands splitting the tumour parenchyma into nodules,
coagulative necrosis, diffuse sheet-like monotonous small
cells with high nuclear/cytoplasmic ratio, diffuse cellular
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atypia and widespread nucleolomegaly. If at least three of
these features were present, the tumour was diagnosed as car-
cinoma; otherwise, the diagnosis of atypical PA was issued.
PAwas diagnosed on the basis of bland non-hyperplastic mor-
phology [15–17].
Immunohistochemical visualisation and assessment
Immunohistochemistry (IHC) was performed on representative
blocks of tumour tissues. For IHC, 3-μm sections were cut on
electrostatic glass slides (Histobond, Marienfeld, Germany).
After deparaffinisation, antigen retrieval was performed in a
microwave oven (3×5 min) using a basic (pH 9.0) tris
(hydroxymethyl) aminomethane/ethylenediaminetetraacetic
acid (Tris/EDTA) buffer (DAKO, Glostrup, Denmark). After
the activity of endogenous peroxidase was blocked, the sec-
tions were incubated with primary antibodies for 60 min in
the magnetic incubation tray at room temperature. To detect
the proliferation activity by Ki-67 expression, monoclonal
mouse antibody against human antigen, cloneMIB-1 (DAKO),
was applied at the dilution 1:100. To detect the expression of
parafibromin, representing the protein product ofHRPT2 gene,
polyclonal rabbit antibody against human antigen (Abcam;
code ab84916) was used at the dilution 1:500. The bound pri-
mary antibodies were detected by the enzyme-conjugated poly-
meric visualisation system EnVision (DAKO), linked with
horseradish peroxidase using 3,3′-diaminobenzidine as the
chromogen (DAKO). Positive and negative quality controls
were invariably performed and reacted appropriately.
Parafibromin expression was evaluated as a categorical vari-
able. A case was considered positive if unequivocal nuclear
reactivity was present in tumour cells; otherwise, the case was
treated as negative [18]. To characterise the expression of Ki-67
by mean proliferation fraction, positive nuclei were counted in
400 consecutive neoplastic cells, and the result was expressed
as the percentage. Computed-assisted morphometry was ap-
plied for quantitative measurements of nuclear positivity, using
NIS-Elements (Nikon, Tokyo, Japan) software to analyse im-
ages that were obtained by. Eclipse Ci-Lmicroscope (Nikon) in
association with DS-Fi2 camera (Nikon).
The immunophenotype was compared among three clini-
cally distinct categories of parathyroid tumours: (1) PC, (2)
atypical adenoma possessing atypical morphology but not ful-
filling PC criteria and associated with high preoperative Ca
level exceeding 2.9 mmol/l and high preoperative PTH ex-
ceeding 250 pg/ml and (3) typical PA lacking all the previous-
ly listed features.
Statistical analysis
The statistical evaluation of the data was carried out using the
Statistical Package for Social Sciences (SPSS® version 20)
software. In addition, CIA software was used to detect the
95 % confidence interval (CI) as described by Altman et al.
[19]. Differences were considered statistically significant if
p<0.05.
Results
The database search yielded 982 eligible patients. The demo-
graphic data and clinical features of the PHPT cohorts from
Pauls Stradins Clinical university hospital, Riga (LAT) and
Lukas hospital, Neuss (GER) are shown in Table 1. Regarding
age, there was no difference between the two European co-
horts. Females were predominantly affected in both groups.
However, the female-to-male ratio differed statistically signif-
icantly (p=0.006), as it was 7:1 in LAT group vs 4:1 among
GER patients.
The mean preoperative Ca and PTH levels were signifi-
cantly higher in LAT group compared to those in GER (p=
0.01; p=0.001, respectively) (Table 1). Preoperative Ca con-
centration exceeded 2.9 mmol/l in 35.1 % (95 % CI=29.8–
40.8) of LAT cases vs 32.0 % (95 % CI=28.6–35.6) GER
patients. Preoperative PTH level exceeded 250 pg/ml in
28.5 % (95 % CI=23.6–34.0) of LAT vs 16.0 % (95 % CI=
Table 1 Demographic data and
clinical features of PHPT patients
in two European cohorts (2005–
2014)
Feature LAT GER p
No. of patients 288 694
Mean age (years)±SD 58.6±12.65 58±13.98 NS
Sex (male/female) 35/253 134/560 0.006
Mean preoperative serum calcium (mmol/l)±SD 2.89±0.34 2.81±0.28 0.01
Mean preoperative serum parathormone (pg/ml)±SD 324.56±403.93 182.54±166.83 0.001
Nephrolithiasis (%) 30.2 28.2 NS
LAT Pauls Stradins Clinical university hospital, Riga, Latvia;GER Lukas hospital, Neuss, Germany; SD standard
deviation; NS not significant
Reference ranges: calcium 2.20–2.60 mmol/l; parathormone 17.00–72.00 pg/ml
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13.5–18.9) in GER group. Both these findings were present in
17.4 % (95 % CI=13.4–22.2) of LAT vs 10.5 % (95 % CI=
8.4–13.0) of GER patients.
PC was confirmed by postoperative histology in 6/288
(2.1 %) LAT and 2/694 (0.3 %) GER patients. The difference
was statistically significant; p=0.004. There was one male PC
patient in LAT group but the remaining five LAT, and both
GER patients were females. The demographic data, clinical
features and results of IHC staining for Ki-67 and
parafibromin are displayed in Table 2. The mean age of PC
diagnostics was 52.2±16.1 years in LAT group. Due to the
low number of cases, the mean age was not used to character-
ise the GER PC patients. In LAT cohort, 4/6 PC cases showed
elevated preoperative Ca above 2.9 mmol/l in combination
with high preoperative PTH >250 pg/ml. The remaining
LAT patients had either elevated Ca (1/6) or PTH (1/6). In
GER group, the only pathological biochemical laboratory
finding was elevated Ca>2.9 mmol/l in a single patient.
In both cohorts, Ki-67 expression was observed in at least
5 % of PC cells (Fig. 1a) except a single case showing prolif-
eration fraction of 4.8 %. The highest proliferative activity
was 22.7 %. IHC expression of parafibromin was invariably
negative in all PC cases (Fig. 1b) contrasting to mostly posi-
tive staining in benign parathyroid tissues (Fig. 2; Table 3).
Further, we analysed the immunophenotype for Ki-67 and
parafibromin expression in clinically distinct parathyroid le-
sions. The mean value of Ki-67 expression in PC was 10.6 %
(95 % CI=4.0–17.1) in LAT group vs 11.0 (95 % CI=0.0–
23.5) in GER patients. The proliferation activity in parathy-
roid adenomas was statistically and biologically significantly
lower, ranging from 1.6 % (95 % CI=1.3–2.0) to 1.6 % (0.7–
2.6) in respect to morphological and biochemical features
(Table 3). To estimate the role of tumour heterogeneity regard-
ing parafibromin expression, the proliferation activity by Ki-
67 was also compared between PC and PA showing focal loss
of parafibromin. However, PA manifesting parafibromin het-
erogeneity also had significantly lower proliferation activity
than carcinomas, namely 2.2 % (95 % CI=0.6–3.8) vs 10.6 %
(95 % CI=4.0–17.1) considering the larger cohort. The rele-
vant data are shown in Table 4.
Discussion
Parathyroid carcinoma (PC) is a very rare endocrine entity, but
highly aggressive form of PHPT. The frequency of PC among
PHPT patients ranges widely between values less than 0.2 %
and exceeding 4 %, if the studies from North America and
most of Europe are compared to those from Asia and Italy,
respectively [20–24]. The rarity of this tumour embarrasses
the genetic studies. Thus, it is not well proven, whether PC
generally arises de novo or from pre-existing benign PA
through the accumulation of genetic abnormalities [25]. There
are some case reports describing PC on the background of
parathyroid adenoma or hyperplasia, but these data are very
scanty [26, 27]. Further, neither imaging nor clinical or labo-
ratory findings can reliably predict PC course in cases lacking
any evidence of metastasis, thus impairing both patient’s care
and reliability of epidemiological studies [28].
Regarding the PC frequency, significant differences were
found between the assessed European PHPT cohorts as PC
was diagnosed in 2.1 % LAT but only in 0.3 % GER patients.
This could be explained by delayed diagnostics. However,
adenoma-to-carcinoma progression has never been shown
for PC. It also could be due to geographic variability or by
selection bias in the patient referral for surgery. To test these
hypotheses, we assessed the demographics, including the age
structure, and the molecular characteristics including prolifer-
ation activity and loss of parafibromin, suggesting HRPT2
mutations. In addition, the possibility of discordant morpho-
logic investigation was excluded by strict adherence to the
diagnostic criteria described in the Materials and methods.
Historically, delayed presentation of PHPT was character-
istic, including functional and structural lesions of the internal





Age Sex Calcium (mmol/l) Parathormone (pg/ml) Ki-67a (%) Parafibrominb
LAT 45 Male 3.76 1869.2 9.7 neg
57 Female 4.07 2031.1 8.3 neg
36 Female 4.20 2331.4 10.3 neg
66 Female 3.96 2176.3 22.7 neg
35 Female 3.03 575.2 4.8 neg
74 Female 3.04 1097.5 5.7 neg
GER 67 Female 3.10 474.4 12.0 neg
52 Female 3.40 165.3 10.0 neg
LAT Pauls Stradins Clinical university hospital, Riga, Latvia;GERLukas hospital, Neuss, Germany; neg negative
Reference ranges: calcium 2.20–2.60 mmol/l; parathormone 17.00–72.00 pg/ml
a Percentage of positive cells
b Expression as a categorical variable
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organs, nephrolithiasis, hypercalcaemic crisis, muscle weak-
ness, pancreatitis or osteitis fibrosa cystica [29, 30]. Nowa-
days, the full-blown clinical picture has become rare in most
PHPT cases but still can be observed in patients with fast
growing parathyroid tumours such as PC. The rapid clinical
progression of PC in the setting of predominantly clinical
diagnostics of PHPT can lead to diagnostics of PC in earlier
age than PA, as it was reported in former publications [31]. At
present, the majority of patients are diagnosed before the typ-
ical PHPT picture occurs, and some may even lack clinical
symptoms at the time of diagnosis [32]. The widespread avail-
ability of biochemical tests can lead to significantly improved
diagnostics in older patients who frequently undergo testing
for Ca in association with diagnostics and treatment of other
concomitant diseases. Consequently, the epidemiological
landscape of PC can now change to the predominance of
patients older than 60 years.
We therefore questioned whether this difference in age dis-
tribution between PC and PA patients still persists. In our
patient cohorts, including 288 LAT and 694 GER patients,
no age difference was found (mean age, 58.6±12.65 vs 58±
13.98 years). Regarding PC, the age ranged widely (35–
4 years), and the mean age was not significantly different from
the general PHPT cohorts. Thus, a subfraction of PC patients
still is diagnosed in young age influencing the mean age; and
aged persons also have been affected. The age analysis also
does not support a difference in the time of PHPT diagnosis in
the two European cohorts, which otherwise could explain the
increased PC frequency among LAT patients. We neither
found a difference in sex ratio between PC and PA patients
as stated by other authors, who demonstrated a female pre-
dominance in PA but rather equal number of females and
males in PC cohorts [33]. The predominance of females was
shown in all our patient groups. However, higher female-to-
male ratio was observed in LAT PHPT patients when com-
pared to PHPT patients from GER (female-to-male ratio, 7:1
vs 4:1).
Altogether, these demographic and clinical data support the
independent development of PA and PC contrasting with the
tumourigenesis in the other organs such as the large bowel.
However, the theory of unrelated genesis of parathyroid tu-
mours has been supported by the assessment of the underlying
mutations in PA and PC as well as gene expression by whole
genome sequencing [34].
Since a progression of PA to PC has been suggested in
some earlier publications [35, 36], higher Ca as well as PTH
levels in LAT cohort when compared to GER patients with
PHPT, in association with higher PC frequency, could have
been interpreted as an evidence of tumour progression. Addi-
tional to the previously described age structure and literature-
based contradictions to the hypothesis of tumour progression,
the experience in MEN1 and MEN2 patients does not demon-
strate adenoma-to-carcinoma sequence. The genetic analysis
seldom demonstrates MEN1 mutations in PC. As few as ten
patients with MEN1 and MEN2 syndromes (seven and three,
respectively) have ever been shown to suffer from malignant
parathyroid tumours [37]. Thus, PC is surprisingly rare in
MEN1 patients, despite the fact that PHPT in MEN1 patients
can be detected early and despite the high recurrence rate of
PHPT even after effective primary surgery [38].
With increasing numbers of HPT-JT families the number of
PC patients will increase. Other sporadic and familial forms of
PHPT however will not change the incidence of PC.
Therefore, with exception of PHPT and HPT-JT families,
PC occurrence lacks any correlation to occurrence of other
Fig. 1 Immunophenotype of the
parathyroid carcinoma. a High
proliferation activity by Ki-67.
Immunoperoxidase (IP), anti-Ki-
67 (clone MIB-1), original
magnification (OM) 400×. b
Complete absence of
parafibromin. Note the presence
of mitotic figure and enlarged
nucleoli. IP, anti-parafibromin,
OM 400×
Fig. 2 Intense nuclear expression of parafibromin in parathyroid
adenoma. Immunoperoxidase, anti-parafibromin, original magnification
400×
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patients with sporadic or familial PHPT. This assumption can
be generalised and also fits for our LAT and GER patient co-
horts. However, germline mutation of HRPT2 gene is respon-
sible for the autosomal dominant HPT-JT syndrome, manifest-
ing as multiple benign and/or malignant parathyroid neoplasms
as well as uterine and renal tumours and ossifying fibromas of
the jaw bones [25, 36]. Germline HRPT2 mutations are also
found in patients with familial isolated hyperparathyroidism
and in up to 20 % of PC patients who have been primarily
classified as sporadic [25], while somatic HRPT2 mutations
are almost exclusively found in up to 77 % of sporadic PC
and in less than 1 % of sporadic PA [4, 6, 7].
Parafibromin represents the protein product ofHRPT2. It is
involved in cell transcription, differentiation, proliferation and
apoptosis. Although the exact way by which this protein in-
creases the malignant potential of PC remains unclear, it is
known to inhibit cyclin D1, which stimulates parathyroid cell
growth [12, 39]. In our two European cohorts, all PC patients
showed diffuse loss of parafibromin by IHC staining. These
data seem surprisingly homogeneous but are in accordance
with other publications in this field. Cohorts with higher num-
ber of PC patients did present loss of parafibromin staining in
approximately 60–100 % [3, 11, 12, 25, 40, 41]. Some of
these differences can be attributable to variable definitions of
malignant behaviour in parathyroid tumours that can be lim-
ited to histologic interpretation only or to clinical follow-up
data. In our study, parafibromin expression in so-called atyp-
ical PAvaried significantly showing either diffuse positivity or
focal loss of expression.
A study by Quinn et al. regarding the utility of parafibromin
and Ki-67 in the differential diagnostics of parathyroid tu-
mours resulted in the conclusion that loss of parafibromin ex-
pression and extent of Ki-67 staining has not been shown to
distinguish between PC and atypical adenoma [42]. Those
findings are contrary to our data confirming higher prolifera-
tion fraction by Ki-67 expression and invariable diffuse loss of
parafibromin in PC. Certain other authors also have reported
high diagnostic value of parafibromin in the diagnostics of
parathyroid carcinoma [15–17]. The study by Witteveen
et al. demonstrated a germline and/or somaticHRPT2mutation
in only four of the 23 PC patients (17 %). These four patients
developed a local recurrence and/or distant metastasis during
follow-up, suggesting that other factors may also have role in
the tumorigenesis of PC [12].
Recently, further studies with new generation genomic se-
quencing enlightened the genomic landscape of recurring spo-
radic PC and depicted multiple somatic mutations in other
genes than HRPT2. Some single nucleotide point mutations
were located to well-known genes such asMTOR, MLL2 and
CDKN2C. Loss of function was found in PIK3CA gene, and
truncating mutations were demonstrated in CDKN2C and
THRAP3 genes. The mutation in PIK3CA encoding for a cat-
alytic subunit of PI3K alters the phosphoinositol pathway,
while CDNK2C mutations impair the inhibition of cyclin-
dependent kinases 4 and 6 [43] that stimulate cellular growth.
Future genetic investigations have to confirm these data and
may lead to specific fingerprints of genetic alterations in PC
resulting in molecular classification that will replace the pres-
ent histology and IHC.
We also analysed Ki-67 expression in benign adenomas
concentrating on different preoperative biochemical features
including Ca and PTH serum levels. Here, we did not find any
statistically significant difference in Ki-67 expression between
the subgroups of adenomas (Table 4). The lack of correlation
between proliferation activity and the functional tumour man-
ifestations also supports the applicability of Ki-67 IHC in the
differential diagnostics of parathyroid tumours.
Table 3 Immunophenotype of parathyroid adenomas in relation to distinct clinical features
Target group Ki-67 Parafibromin
Mean±SD 95 % CI Frequency (%) 95 % CI
Adenoma (atypical morphology, preoperative Ca>2.9 mmol/l, preoperative PTH>250 pg/ml) 1.6±1.00 1.3–2.0 97.5 86.0–100.0
Adenoma (preoperative Ca<2.9 mmol/l, preoperative PTH<250 pg/ml) 1.6±1.53 0.7–2.6 100.0 89.1–100.0
SD standard deviation, CI confidence interval, Ca serum calcium level, PTH serum parathormone level
Reference ranges: calcium 2.20–2.60 mmol/l; parathormone 17.00–72.00 pg/ml
Table 4 Descriptive statistics of proliferation activity by Ki-67
expression in parathyroid tumours showing diffuse vs focal loss of
parafibromin
Target group Ki-67 Parafibromin
Mean±SD 95 % CI Expression
Parathyroid carcinoma
LAT (n=6) 10.6±6.23 4.0–17.1 Diffuse loss (6/6)
GER (n=2) 11.0±1.40 0–23.5 Diffuse loss (2/2)
Atypical adenoma+Ca>2.9 mmol/l and PTH>250 pg/ml
LAT (n=7) 2.2±1.70 0.6–3.8 Focal loss (7/7)
GER (n=3) 1.1±0.53 0.6–1.6 Focal loss (3/3)
SD standard deviation; CI confidence interval; n absolute number; LAT
Pauls Stradins Clinical university hospital, Riga, Latvia; GER Lukas hos-
pital, Neuss, Germany
Reference ranges: calcium 2.20–2.60 mmol/l; parathormone 17.00–
72.00 pg/ml
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Since histologic features and clinical behaviour of parathy-
roid tumours sometimes differ substantially in the follow-up
of patients with PC (recurrence and metastasis in histological-
ly seemingly benign tumours as well as long-standing cure of
PC by surgery alone), an additional measurement still seems
necessary. Whether detection of genetic alteration patterns
may fulfil these expectations and will be able to differentiate
between benign and malignant parathyroid tumours, at pres-
ent, is still unknown.
Focusing on the histology as the predictor of clinical course
in PC, several morphologic evaluation systems have been re-
ported. Those described by Schantz and Castleman are the
most widely used, when PC have to be separated from benign
parathyroid tumours [44]. Metastasis and clear-cut invasion
remain among the cardinal properties of malignant tumours.
The additional morphological features include capsular inva-
sion, presence of trabecular patterns and mitotic figures as
well as the presence of fibrous bands. In our study, we also
based PC diagnosis on the cardinal tumour signs. However, it
still is important to consider the overall clinical picture rather
than any single histopathological criteria, when future out-
come is prospectively assumed [45].
Thus, significant geographic differences in the PC frequen-
cy among the European PHPT patients have shown in the
present study. As the age structure and molecular characteris-
tics of PC in both cohorts are similar, biases in patient referral
for surgery may be considered as the main underlying cause.
Reliable and unified diagnostics should be a cornerstone of the
scientific evaluation of rare diseases. The increased prolifera-
tion fraction and loss of parafibromin are important molecular
features of parathyroid carcinoma that are equally applicable
to both tested cohorts. The future studies should elaborate
novel morphological and molecular diagnostic tests, consid-
ering also the markers explored in the present study.
Limitations of our study are the retrospective analysis of
data, lack of epidemiological information concerning the
prevalence of PC in Latvian and German population and the
low number of patients with PC.
Conclusions
PC frequency can range significantly between the two Euro-
pean cohorts. The differences can be attributable to selection
bias of patients referred for surgery and are not caused by
discordant definition of malignant parathyroid histology.
The identification of the parafibromin, encoded by HRPT2
gene, has provided an important insight in the molecular path-
ogenesis of PC. Total loss of parafibromin staining and in-
creased proliferation fraction by Ki-67 are valuable adjuncts
that may help in differentiating between atypical adenomas
and PC.
Authors’ contributions
& Study conception and design: Arturs Ozolins, Peter E. Goretzki,
Zenons Narbuts and Ilze Strumfa
& Acquisition of data: Arturs Ozolins, Zane Visnevska, Aycan Akca,
Denis Wirowski*, Zane Simtniece, Ilze Strumfa and Peter E.
Goretzki
& Analysis and interpretation of data: Arturs Ozolins, Andrejs Vanags,
Zane Simtniece, Zenons Narbuts, Aycan Akca and Peter E. Goretzki
& Drafting of manuscript: Arturs Ozolins, Zenons Narbuts, Ilze
Strumfa and Peter E. Goretzki
& Critical revision of manuscript: Arturs Ozolins, Zenons Narbuts,
Andrejs Vanags, Ilze Strumfa, Janis Gardovskis and Peter E.
Goretzki
Compliance with ethical standards The study was performed in ac-
cordance with the Declaration of Helsinki and permission of the Com-
mittee of Ethics, Riga Stradins University (No. E-9(2), issued onMay 5th,
2014). The present work was carried out within the frames of scientific
project Nr. 2013/0004/1DP/1.1.1.2.0/13/APIA/VIAA/ 020, supported by
the European Social Fund (ESF). This article does not contain any studies
with human participants or animals performed by any of the authors.
Conflicts of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Cetani F, Banti C, Pardi E, Borsari S, Viacava P, Miccoli P,
Torregrossa L, Basolo F, Pelizzo MR, Rugge M, Pennelli G,
Gasparri G, Papotti M, Volante M, Vignali E, Saponaro F,
Marcocci C (2013) CDC73 mutational status and loss of
parafibromin in the outcome of parathyroid cancer. Endocrine con-
nections 2(4):186–195. doi:10.1530/EC-13-0046
2. Allen ME, Semrad A, Yang AD, Martinez SR (2013)
Parathyroid carcinoma survival: improvements in the era of
intact parathyroid hormone monitoring? Rare tumors 5(1),
e12. doi:10.4081/rt.2013.e12
3. Wilkins BJ, Lewis JS Jr (2009) Non-functional parathyroid carci-
noma: a review of the literature and report of a case requiring ex-
tensive surgery. Head Neck Pathol 3(2):140–149. doi:10.1007/
s12105-009-0115-4
4. Witteveen JE, Haak HR, Kievit J, Morreau H, Romijn JA, Hamdy
NA (2010) Challenges and pitfalls in the management of parathy-
roid carcinoma: 17-year follow-up of a case and review of the
literature. Hormones & cancer 1(4):205–214. doi:10.1007/
s12672-010-0042-6
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1999) Two
hundred eighty-six cases of parathyroid carcinoma treated in the
U.S. between 1985–1995: a National Cancer Data Base Report.
The American College of Surgeons Commission on Cancer and
the American Cancer Society. Cancer 86(3):538–544
Langenbecks Arch Surg (2016) 401:943–951 949
6. Rawat N, Khetan N, Williams DW, Baxter JN (2005) Parathyroid
carcinoma. Br J Surg 92(11):1345–1353. doi:10.1002/bjs.5182
7. Lihara M, Okamoto T, Suzuki R, Kawamata A, Nishikawa T,
Kobayashi M, Obara T (2007) Functional parathyroid carci-
noma: long-term treatment outcome and risk factor analysis.
Surgery 142(6):936–943. doi:10.1016/j.surg.2007.09.014,
discussion 943 e931
8. Thompson L (2006) World Health Organization classification of
tumours: pathology and genetics of head and neck tumours. Ear
Nose Throat J 85(2):74
9. Koea JB, Shaw JH (1999) Parathyroid cancer: biology and man-
agement. Surg Oncol 8(3):155–165
10. Kleinpeter KP, Lovato JF, Clark PB, Wooldridge T, Norman ES,
Bergman S, Perrier ND (2005) Is parathyroid carcinoma indeed a
lethal disease? Ann Surg Oncol 12(3):260–266. doi:10.1245/ASO.
2005.03.036
11. Gill AJ (2014) Understanding the genetic basis of parathyroid car-
cinoma. Endocr Pathol 25(1):30–34. doi:10.1007/s12022-013-
9294-3
12. Witteveen JE, HamdyNA, Dekkers OM,Kievit J, vanWezel T, Teh
BT, Romijn JA, Morreau H (2011) Downregulation of CASR ex-
pression and global loss of parafibromin staining are strong nega-
tive determinants of prognosis in parathyroid carcinoma. Mod
Pathol 24(5):688–697. doi:10.1038/modpathol.2010.236
13. Lloyd RV, Carney JA, Ferreiro JA, Jin L, Thompson GB, Van
Heerden JA, Grant CS, Wollan PC (1995) Immunohistochemical
analysis of the cell cycle-associated antigens Ki-67 and retinoblas-
toma protein in parathyroid carcinomas and adenomas. Endocr
Pathol 6(4):279–287
14. Juhlin CC, Hoog A (2010) Parafibromin as a diagnostic instrument
for parathyroid carcinoma-lone ranger or part of the posse? Int J
Endocrinol 2010:324964. doi:10.1155/2010/324964
15. Kruijff S, Sidhu SB, Sywak MS, Gill AJ, Delbridge LW (2014)
Negative parafibromin staining predicts malignant behavior in atyp-
ical parathyroid adenomas. Ann Surg Oncol 21(2):426–433. doi:10.
1245/s10434-013-3288-8
16. Kim HK, Oh YL, Kim SH, Lee DY, Kang HC, Lee JI, Jang HW,
Hur KY, Kim JH, Min YK, Chung JH, Kim SW (2012)
Parafibromin immunohistochemical staining to differentiate para-
thyroid carcinoma from parathyroid adenoma. Head Neck 34(2):
201–206. doi:10.1002/hed.21716
17. Wang O, Wang CY, Shi J, Nie M, Xia WB, Li M, Jiang Y, Guan H,
Meng XW, Xing XP (2012) Expression of Ki-67, galectin-3, fragile
histidine triad, and parafibromin in malignant and benign parathy-
roid tumors. Chin Med J 125(16):2895–2901
18. Guarnieri V, Battista C,Muscarella LA, Bisceglia M, deMartino D,
Baorda F, Maiello E, D'Agruma L, Chiodini I, Clemente C,
Minisola S, Romagnoli E, Corbetta S, Viti R, Eller-Vainicher C,
Spada A, Iacobellis M, Malavolta N, Carella M, Canaff L, Hendy
GN, Cole DE, Scillitani A (2012) CDC73 mutations and
parafibromin immunohistochemistry in parathyroid tumors: clinical
correlations in a single-centre patient cohort. Cell Oncol 35(6):411–
422. doi:10.1007/s13402-012-0100-x
19. Altman DG (2000) ROC curves and confidence intervals: getting
them right. Heart 83(2):236
20. Sadler C, Gow KW, Beierle EA, Doski JJ, Langer M, Nuchtern JG,
Vasudevan SA, Goldfarb M (2014) Parathyroid carcinoma in more
than 1,000 patients: a population-level analysis. Surgery 156(6):
1622–1629. doi:10.1016/j.surg.2014.08.069, discussion 1629–
1630
21. Lumachi F, Basso SM, Basso U (2006) Parathyroid cancer: etiolo-
gy, clinical presentation and treatment. Anticancer Res 26(6C):
4803–4807
22. Lee YS, Hong SW, Jeong JJ, Nam KH, Chung WY, Chang HS,
Park CS (2010) Parathyroid carcinoma: a 16-year experience in a
single institution. Endocr J 57(6):493–497
23. IacoboneM, Lumachi F, Favia G (2004) Up-to-date on parathyroid
carcinoma: analysis of an experience of 19 cases. J Surg Oncol
88(4):223–228. doi:10.1002/jso.20152
24. Zhao L, Liu JM, He XY, Zhao HY, Sun LH, Tao B, Zhang MJ,
Chen X, Wang WQ, Ning G (2013) The changing clinical patterns
of primary hyperparathyroidism in Chinese patients: data from
2000 to 2010 in a single clinical center. J Clin Endocrinol Metab
98(2):721–728. doi:10.1210/jc.2012-2914
25. Costa-Guda J, Arnold A (2014) Genetic and epigenetic changes in
sporadic endocrine tumors: parathyroid tumors. Mol Cell
Endocrinol 386(1–2):46–54. doi:10.1016/j.mce.2013.09.005
26. Murayama T, Kawabe K, Tagami M (1977) A case of parathyroid
carcinoma concurred with hyperplasia: an electron microscopic
study. J Urol 118(1 Pt 1):126–127
27. Desch CE, Arsensis G, Woolf PD, May AG, Amatruda JM (1984)
Parathyroid hyperplasia and carcinoma within one gland. Am J
Med 77(1):131–134
28. Karakas E, Muller HH, Lyadov VK, Luz S, Schneider R,
Rothmund M, Bartsch DK, Schlosser K (2012) Development of a
formula to predict parathyroid carcinoma in patients with primary
hyperparathyroidism. World J Surg 36(11):2605–2611. doi:10.
1007/s00268-012-1707-9
29. Belcher R, Metrailer AM, Bodenner DL, Stack BC Jr (2013)
Characterization of hyperparathyroidism in youth and adolescents:
a literature review. Int J Pediatr Otorhinolaryngol 77(3):318–322.
doi:10.1016/j.ijporl.2012.12.008
30. Hyperparathyroidism AATFoP (2005) The American Association
of Clinical Endocrinologists and the American Association of
Endocrine Surgeons position statement on the diagnosis and man-
agement of primary hyperparathyroidism. Endocr Pract 11(1):49–
54. doi:10.4158/EP.11.1.49
31. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R,
Marcocci C, Potts JT Jr (2014) Guidelines for the management of
asymptomatic primary hyperparathyroidism: summary statement
from the Fourth International Workshop. J Clin Endocrinol Metab
99(10):3561–3569. doi:10.1210/jc.2014-1413
32. Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW
(1991) Characterization and evaluation of asymptomatic primary
hyperparathyroidism. J Bone Miner Res Off J Am Soc Bone
Miner Res 6(Suppl 2):S85–S89. doi:10.1002/jbmr.5650061419,
discussion S121-124
33. Talat N, Schulte KM (2010) Clinical presentation, staging and long-
term evolution of parathyroid cancer. Ann Surg Oncol 17(8):2156–
2174. doi:10.1245/s10434-010-1003-6
34. Oltmann SC, Rajaei MH, Sippel RS, Chen H, Schneider DF (2014)
Primary hyperparathyroidism across the ages: presentation and out-
comes. J Surg Res 190(1):185–190. doi:10.1016/j.jss.2014.04.010
35. Levin KE, Galante M, Clark OH (1987) Parathyroid carcinoma
versus parathyroid adenoma in patients with profound hypercalce-
mia. Surgery 101(6):649–660
36. Gill AJ, Clarkson A, GimmO, Keil J, Dralle H, Howell VM,Marsh
DJ (2006) Loss of nuclear expression of parafibromin distinguishes
parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-
JT) syndrome-related adenomas from sporadic parathyroid adeno-
mas and hyperplasias. Am J Surg Pathol 30(9):1140–1149. doi:10.
1097/01.pas.0000209827.39477.4f
37. Carling T, Udelsman R (2005) Parathyroid surgery in familial
hyperparathyroid disorders. J Intern Med 257(1):27–37. doi:10.
1111/j.1365-2796.2004.01428.x
38. Machens A, Lorenz K, Dralle H (2013) Peak incidence of pheo-
chromocytoma and primary hyperparathyroidism in multiple endo-
crine neoplasia 2: need for age-adjusted biochemical screening. J
Clin Endocrinol Metab 98(2):E336–E345. doi:10.1210/jc.2012-
3192
39. Newey PJ, BowlMR, Cranston T, Thakker RV (2010) Cell division
cycle protein 73 homolog (CDC73) mutations in the
950 Langenbecks Arch Surg (2016) 401:943–951
hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathy-
roid tumors. Hum Mutat 31(3):295–307. doi:10.1002/humu.21188
40. Diaconescu MR, Glod M, Costea I, Grigorovici M, Diaconescu S
(2015) Clinicopathological phenotype of parathyroid carcinoma:
therapeutic and prognostic aftermaths. Chirurgia 110(1):66–71
41. Weinstein LS, Simonds WF (2003) HRPT2, a marker of parathy-
roid cancer. N Engl J Med 349(18):1691–1692. doi:10.1056/
NEJMp038159
42. Quinn CE, Healy J, Lebastchi AH, Brown TC, Stein JE, Prasad
ML, Callender GG, Carling T, Udelsman R (2015) Modern expe-
rience with aggressive parathyroid tumors in a high-volume New
England referral center. J Am Coll Surg 220(6):1054–1062. doi:10.
1016/j.jamcollsurg.2014.10.007
43. Kasaian K, Wiseman SM, Thiessen N, Mungall KL, Corbett
RD, Qian JQ, Nip KM, He A, Tse K, Chuah E, Varhol RJ,
Pandoh P, McDonald H, Zeng T, Tam A, Schein J, Birol I,
Mungall AJ, Moore RA, Zhao Y, Hirst M, Marra MA, Walker
BA, Jones SJ (2013) Complete genomic landscape of a recur-
ring sporadic parathyroid carcinoma. J Pathol 230(3):249–260.
doi:10.1002/path.4203
44. Schantz A, Castleman B (1973) Parathyroid carcinoma. A study of
70 cases. Cancer 31(3):600–605
45. Betea D, Potorac I, Beckers A (2015) Parathyroid carcinoma: chal-
lenges in diagnosis and treatment. Ann Endocrinol 76(2):169–177.
doi:10.1016/j.ando.2015.03.003
Langenbecks Arch Surg (2016) 401:943–951 951
